Efficacy, Safety, and Feasibility of the Morphine Microdose Method in Community-Based Clinics

Denise Wilkes, Susan J. Orillosa, Erik Hustak, Courtney Williams, Gulshan Doulatram, Daneshvari R. Solanki, Eduardo A. Garcia, Li-Yen Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: The goal of this study was to assess the success of the morphine microdose method in a community pain clinic setting by monitoring follow-up frequency, dose escalation, and monotherapy/polytherapy ratio. The morphine microdose method involves a pretrial reduction or elimination of systemic opioids followed by a period of abstinence. Intrathecal (IT) morphine is then started at doses of less than 0.2 mg per day. Systemic opioid abstinence is then continued after pump implant and IT morphine monotherapy. Design: Retrospective review of medical records. Setting: Private and academic pain clinic practices. Subjects: Chronic noncancer pain patients. Methods: We reviewed the charts of 60 patients who had completed a microdose regimen and had an IT pump implanted between June 11, 2008, and October 11, 2014. During IT therapy, dose change over time, pain scores, side effects, max dose, and duration were recorded. Results: The majority of patients (35/60, 58%) were successfully managed solely on morphine microdose monotherapy. These patients did not require additional oral therapy. There was a significant reduction in mean pain scores, from 7.4 ± 0.32 before microdose therapy to 4.8 ± 0.3 after microdose therapy. Conclusions: Microdose therapy achieved analgesia, improved safety, and avoided systemic side effects. The safety of IT therapy was increased by using a lower concentration (2 mg/mL) and lower daily doses (<3 mg/d) of morphine. Furthermore, microdose therapy was feasible, safe, and cost-effective in the outpatient setting.

Original languageEnglish (US)
Pages (from-to)1782-1789
Number of pages8
JournalPain medicine (Malden, Mass.)
Volume19
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Morphine
Safety
Pain Clinics
Opioid Analgesics
Therapeutics
Pain
Chronic Pain
Analgesia
Medical Records
Outpatients
Costs and Cost Analysis

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Efficacy, Safety, and Feasibility of the Morphine Microdose Method in Community-Based Clinics. / Wilkes, Denise; Orillosa, Susan J.; Hustak, Erik; Williams, Courtney; Doulatram, Gulshan; Solanki, Daneshvari R.; Garcia, Eduardo A.; Huang, Li-Yen.

In: Pain medicine (Malden, Mass.), Vol. 19, No. 9, 01.09.2018, p. 1782-1789.

Research output: Contribution to journalArticle

@article{e4e3dc7b6a89418f8fc4d5b313d6d318,
title = "Efficacy, Safety, and Feasibility of the Morphine Microdose Method in Community-Based Clinics",
abstract = "Objectives: The goal of this study was to assess the success of the morphine microdose method in a community pain clinic setting by monitoring follow-up frequency, dose escalation, and monotherapy/polytherapy ratio. The morphine microdose method involves a pretrial reduction or elimination of systemic opioids followed by a period of abstinence. Intrathecal (IT) morphine is then started at doses of less than 0.2 mg per day. Systemic opioid abstinence is then continued after pump implant and IT morphine monotherapy. Design: Retrospective review of medical records. Setting: Private and academic pain clinic practices. Subjects: Chronic noncancer pain patients. Methods: We reviewed the charts of 60 patients who had completed a microdose regimen and had an IT pump implanted between June 11, 2008, and October 11, 2014. During IT therapy, dose change over time, pain scores, side effects, max dose, and duration were recorded. Results: The majority of patients (35/60, 58{\%}) were successfully managed solely on morphine microdose monotherapy. These patients did not require additional oral therapy. There was a significant reduction in mean pain scores, from 7.4 ± 0.32 before microdose therapy to 4.8 ± 0.3 after microdose therapy. Conclusions: Microdose therapy achieved analgesia, improved safety, and avoided systemic side effects. The safety of IT therapy was increased by using a lower concentration (2 mg/mL) and lower daily doses (<3 mg/d) of morphine. Furthermore, microdose therapy was feasible, safe, and cost-effective in the outpatient setting.",
author = "Denise Wilkes and Orillosa, {Susan J.} and Erik Hustak and Courtney Williams and Gulshan Doulatram and Solanki, {Daneshvari R.} and Garcia, {Eduardo A.} and Li-Yen Huang",
year = "2018",
month = "9",
day = "1",
doi = "10.1093/pm/pnx132",
language = "English (US)",
volume = "19",
pages = "1782--1789",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Efficacy, Safety, and Feasibility of the Morphine Microdose Method in Community-Based Clinics

AU - Wilkes, Denise

AU - Orillosa, Susan J.

AU - Hustak, Erik

AU - Williams, Courtney

AU - Doulatram, Gulshan

AU - Solanki, Daneshvari R.

AU - Garcia, Eduardo A.

AU - Huang, Li-Yen

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objectives: The goal of this study was to assess the success of the morphine microdose method in a community pain clinic setting by monitoring follow-up frequency, dose escalation, and monotherapy/polytherapy ratio. The morphine microdose method involves a pretrial reduction or elimination of systemic opioids followed by a period of abstinence. Intrathecal (IT) morphine is then started at doses of less than 0.2 mg per day. Systemic opioid abstinence is then continued after pump implant and IT morphine monotherapy. Design: Retrospective review of medical records. Setting: Private and academic pain clinic practices. Subjects: Chronic noncancer pain patients. Methods: We reviewed the charts of 60 patients who had completed a microdose regimen and had an IT pump implanted between June 11, 2008, and October 11, 2014. During IT therapy, dose change over time, pain scores, side effects, max dose, and duration were recorded. Results: The majority of patients (35/60, 58%) were successfully managed solely on morphine microdose monotherapy. These patients did not require additional oral therapy. There was a significant reduction in mean pain scores, from 7.4 ± 0.32 before microdose therapy to 4.8 ± 0.3 after microdose therapy. Conclusions: Microdose therapy achieved analgesia, improved safety, and avoided systemic side effects. The safety of IT therapy was increased by using a lower concentration (2 mg/mL) and lower daily doses (<3 mg/d) of morphine. Furthermore, microdose therapy was feasible, safe, and cost-effective in the outpatient setting.

AB - Objectives: The goal of this study was to assess the success of the morphine microdose method in a community pain clinic setting by monitoring follow-up frequency, dose escalation, and monotherapy/polytherapy ratio. The morphine microdose method involves a pretrial reduction or elimination of systemic opioids followed by a period of abstinence. Intrathecal (IT) morphine is then started at doses of less than 0.2 mg per day. Systemic opioid abstinence is then continued after pump implant and IT morphine monotherapy. Design: Retrospective review of medical records. Setting: Private and academic pain clinic practices. Subjects: Chronic noncancer pain patients. Methods: We reviewed the charts of 60 patients who had completed a microdose regimen and had an IT pump implanted between June 11, 2008, and October 11, 2014. During IT therapy, dose change over time, pain scores, side effects, max dose, and duration were recorded. Results: The majority of patients (35/60, 58%) were successfully managed solely on morphine microdose monotherapy. These patients did not require additional oral therapy. There was a significant reduction in mean pain scores, from 7.4 ± 0.32 before microdose therapy to 4.8 ± 0.3 after microdose therapy. Conclusions: Microdose therapy achieved analgesia, improved safety, and avoided systemic side effects. The safety of IT therapy was increased by using a lower concentration (2 mg/mL) and lower daily doses (<3 mg/d) of morphine. Furthermore, microdose therapy was feasible, safe, and cost-effective in the outpatient setting.

UR - http://www.scopus.com/inward/record.url?scp=85062900742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062900742&partnerID=8YFLogxK

U2 - 10.1093/pm/pnx132

DO - 10.1093/pm/pnx132

M3 - Article

VL - 19

SP - 1782

EP - 1789

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 9

ER -